Clinical Trials on Lung Squamous Cell Carcinoma in Japan

Total 545 results

Shiga University
University of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaborators

Unknown

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
Eisai Co., Ltd.

Completed

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Japan
AstraZeneca

Terminated

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Completed

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Bristol-Myers Squibb

Completed

Study of BMS-986012 in Subjects With Small Cell Lung Caner

Small Cell Lung Cancer

Japan
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Terminated

A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Esophageal Neoplasms

Japan
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, Taiwan, China, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Pfizer

Completed

Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Non-squamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom
Daiichi Sankyo Co., Ltd.

Completed

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Cervical Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gastric Cancer (Inoperable and Recurrent)

Japan
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Japan Multinational Trial Organization

Completed

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

Lung Cancer

Japan
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Boehringer Ingelheim

Completed

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Russian Federation, South Africa, Spain, Sweden, Switzerland
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan
Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan
Hoffmann-La Roche

Completed

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Austria, Denmark, Italy, Spain, Germany, Mexico, Netherlands, Japan, Brazil, Greece, Argentina, Slovakia, Lebanon, Belgium, Oman, United Arab Emirates
GAIA BioMedicine Inc.

Recruiting

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

NSCLC | Cell Therapy

Japan
AstraZeneca

Completed

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

Japan
AstraZeneca

Completed

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,

Japan
Eli Lilly and Company

Completed

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Non Small Cell Lung Cancer

Japan
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
Eli Lilly and Company

Completed

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Ovarian Cancer | Advanced Solid Tumors

Japan, Korea, Republic of
Eli Lilly and Company

Completed

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

Japan
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Patients With Small Cell Lung Carcinoma and Other Neoplasms

United States, Spain, Germany, Japan
Boehringer Ingelheim

Recruiting

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREONᵀᴹ-8)

Small Cell Lung Carcinoma (SCLC)

Spain, Belgium, Japan, France, Poland, Germany
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Advanced or Metastatic Renal Cell Carcinoma

Japan
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
AbbVie

Completed

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
Japan Multinational Trial Organization

Completed

Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Japan
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
University of Toyama

Unknown

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer (RNCLC)

Small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Yamagata University

Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

Metastatic Renal Cell Carcinoma

Japan
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Telix International Pty Ltd

Completed

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (ZIRDAC-JP)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Japan
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Completed

Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)

Non-Small-Cell Lung Carcinoma

Japan

Clinical Trials on Lung Squamous Cell Carcinoma in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations